Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-09-10 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思重大信息内部报告制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '重大信息内部报告制度' (Major Information Internal Reporting System) of 杭州安杰思医学科技股份有限公司. It outlines the procedures, responsibilities, and scope for reporting major information that could affect the company's stock price, including definitions, reporting obligations, confidentiality, and legal responsibilities. It references relevant laws and regulations but does not contain financial statements, earnings data, or any form of financial results. It is not a report of financial performance, audit, or management discussion, nor is it an announcement or presentation. It is a governance-related document detailing internal rules and procedures for information disclosure and reporting within the company. Therefore, it fits best under Governance Information (CGR). The document length (6707 characters) and content confirm it is a substantive policy document, not a brief announcement or certification.
2025-09-10 Chinese
安杰思对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '杭州安杰思医学科技股份有限公司 对外投资管理制度' which translates to 'Hangzhou Anjiese Medical Technology Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the principles, approval authorities, management, disposal, financial management, and auditing procedures related to the company's external investments. The content focuses on governance, internal controls, and procedural rules rather than financial results, earnings, or regulatory announcements. There is no indication that this is a report of financial performance, audit, or a regulatory filing. It is not a presentation, call transcript, or announcement of voting results. The document is a governance-related internal control policy, which fits best under Governance Information (CGR). The document length (6024 characters) and detailed procedural content support this classification with high confidence.
2025-09-10 Chinese
安杰思关于取消监事会并修订《公司章程》及制定、废止、修订部分公司治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Hangzhou Anjiese Medical Technology Co., Ltd. regarding the cancellation of the Supervisory Board, amendments to the company's Articles of Association, and the formulation, abolition, and revision of certain corporate governance systems. It includes extensive legal and regulatory references, detailed changes to governance structures, shareholder rights, board responsibilities, and compliance with laws and stock exchange rules. The content focuses on governance structure changes and corporate governance rules rather than financial results, audit opinions, or capital changes. It is not a financial report, earnings release, or capital update. It is not a proxy statement or voting results announcement. The document is a governance-related announcement detailing changes to the company's internal rules and governance practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement of a report publication or a regulatory filing. Confidence is high due to the specificity and depth of governance content.
2025-09-10 Chinese
安杰思关于2023年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期符合归属条件的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the fulfillment of conditions for the second vesting period of the first grant and the first vesting period of the reserved grant under the 2023 restricted stock incentive plan. It includes extensive information about the stock incentive plan, vesting schedules, performance targets, individual and company-level performance assessments, board and supervisory committee approvals, legal opinions, and the number of shares vested or canceled. The document is not a financial report, earnings release, or regulatory filing in the usual sense but is a formal announcement related to the company's stock incentive plan and the vesting of restricted shares. This type of announcement is best classified under Regulatory Filings (RNS) as it does not fit the other more specific categories such as Remuneration Information (DEF 14A) or Board/Management Information (MANG). It is a regulatory disclosure about stock incentive vesting conditions and results, which is typical for RNS filings in the Chinese market context.
2025-09-10 Chinese
安杰思信息披露管理制度
Governance Information Classification · 95% confidence The document is a detailed information disclosure system policy of a company, outlining principles, types of reports, disclosure obligations, and procedures related to information disclosure. It references various types of reports such as annual reports, quarterly reports, interim reports, and temporary reports, but it is not itself any of these reports. Instead, it is a governance and procedural document about how the company manages and discloses information to investors and regulators. It does not contain financial data, audit opinions, or actual report content. It is a regulatory or governance framework document. Therefore, the most appropriate classification is Governance Information (CGR).
2025-09-10 Chinese
安杰思募集资金管理办法
Governance Information Classification · 95% confidence The document is titled '募集资金管理办法' which translates to 'Fundraising Capital Management Measures' and is issued by 杭州安杰思医学科技股份有限公司 (Hangzhou Anjisi Medical Technology Co., Ltd.). The content details the rules and procedures for managing and using funds raised through stock issuance or other equity securities, including storage, usage, supervision, and reporting requirements. It references relevant Chinese laws and Shanghai Stock Exchange regulations. The document is a detailed internal policy or management guideline on fundraising capital management rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or other report types. It is a governance-related document outlining internal rules and governance practices related to fundraising capital. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7778 characters) supports it being a substantive policy document rather than a short announcement or certification.
2025-09-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.